文献速递认知障碍与痴呆

助听器治疗听力损失以预防认知下降和痴呆

Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia.
PubMed 文献 · Neurology · 2026-01-14

该研究采用目标试验模拟方法,基于ASPirin in Reducing Events in the Elderly研究中的澳大利亚参与者数据,评估助听器使用对听力障碍老年人认知和痴呆风险的影响。结果显示,助听器处方与7年痴呆风险降低相关(5.0% vs 7.5%,RR 0.67;95%CI 0.37-0.97),认知损害风险也降低(36.1% vs 42.4%,RR 0.85;95%CI 0.70-1.00),但总体认知评分无显著差异(平均差0.03 SD;95%CI -0.14 to 0.21)。

要点

  • 助听器使用可能降低听力障碍老年人痴呆风险。
  • 助听器使用频率越高,痴呆和认知损害风险越低。
  • 助听器对总体认知评分无显著影响。

核心结论

  • 助听器使用可能降低听力障碍老年人的痴呆风险,但对年龄相关认知变化的影响不显著。

研究设计与样本

  • 采用目标试验模拟方法,数据来自ASPirin in Reducing Events in the Elderly研究的澳大利亚参与者,纳入无痴呆、中度听力障碍且未使用过助听器的老年人,中位纳入2777人,中位接受新助听器处方664人,平均年龄75岁,48%为女性。

主要发现

  • 助听器处方组与未处方组7年总体认知评分相似(平均差0.03 SD;95%CI -0.14 to 0.21)。
  • 助听器处方组7年痴呆风险为5.0%,未处方组为7.5%(RR 0.67;95%CI 0.37-0.97)。
  • 助听器处方组7年认知损害风险为36.1%,未处方组为42.4%(RR 0.85;95%CI 0.70-1.00)。
  • 痴呆和认知损害风险与助听器使用频率呈负相关。

临床怎么用

  • 对于有中度听力障碍的老年人,考虑推荐使用助听器以可能降低痴呆风险。

局限性

  • 不能排除残余混杂因素对结果的影响。
  • 需要长期随机试验来验证助听器对痴呆风险的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Hearing loss is a risk factor of cognitive decline and dementia. We sought to investigate the effect of hearing aid (HA) use on cognition and dementia risk in older adults with hearing impairment. METHODS: We emulated a target trial using data from Australian participants of the ASPirin in Reducing Events in the Elderly study. In the target trial, eligible participants were dementia-free, had moderate hearing impairment, and had no previous HA use. The treatment strategies were "use HAs" and "do not use HAs." Outcomes included overall cognition, dementia (DSM-IV criteria), and cognitive impairment (cognitive decline or dementia). The emulation used new HA prescription and frequency-of-use data measured by questionnaire, as well as cognition data from semiannual assessments over 7 years. Self-reported hearing problems were used as a proxy for moderate hearing impairment. Using the parametric g-formula, we estimated observational analogs of the intention-to-treat effect, using HA prescription to emulate allocation. Analyses for cognition outcomes were restricted to survivors. Multiple imputation was used for missing covariate and cognitive outcome data. We also emulated a second target trial with treatment strategies of (1) never, (2) rarely/sometimes, and (3) often/always use HAs. RESULTS: Across imputed data sets, a median of 2,777 eligible individuals were included, with a median of 664 receiving a new HA prescription. The mean age was 75 years, and 48% were female. The estimated 7-year mean overall cognition scores among survivors were similar under HA prescription and no HA prescription (mean difference 0.03 SDs; 95% CI -0.14 to 0.21). The estimated 7-year risk of dementia was 5.0% under HA prescription and 7.5% under no HA prescription (risk ratio [RR] 0.67; 95% CI 0.37-0.97), and that of cognitive impairment was 36.1% under HA prescription and 42.4% under no HA prescription (RR 0.85; 95% CI 0.70-1.00). The risks of dementia and cognitive impairment were inversely associated with the frequency of HA use. DISCUSSION: We found that HA use in older people with hearing impairment may reduce dementia risk, although differences in age-related cognitive change were insubstantial. We cannot rule out residual confounding as an explanation for our findings. Long-term randomized trials of HAs for dementia risk are justified. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the use of hearing aids did not change overall cognitive scores in people 70 years and older with moderate hearing impairment as compared to those who used hearing aids.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cribb L, Moreno-Betancur M, Pase MP, et al. Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia. Neurology. 2026. PMID: 41534012. doi:10.1212/WNL.0000000000214572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。